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Abstract 
This study aimed to characterise both neuronal autoantibodies and levels of 
IFNα, two proposed causative agents in neuropsychiatric systemic lupus 
erythematosus (NPSLE). CSF and plasma from 35 SLE patients (15 with 
NPSLE) showed no antibodies against natively-expressed NMDA receptors, or 
the surface of live hippocampal neurons. By comparison to controls (n=104), 
SLE patient antibodies bound a peptide representing the extracellular domain 
of NMDARs (p<0.0001), however, binding was retained against rearranged 
peptides and no peptide (r=0.85 and r=0.79, respectively, p<0.0001). IFNα 
levels were higher in SLE (p<0.0001), without specificity for NPSLE. Neuronal-
surface reactive autoantibodies are not detectable in NPSLE. Our findings 
mandate a search for novel biomarkers in this condition.  
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Introduction 
Systemic Lupus Erythematosus (SLE) is a multi-system autoimmune disease 
associated with antibodies against native DNA. A subset of patients have 
neuropsychiatric SLE (NPSLE), a disabling clinical syndrome with widely varied 
features including headache, seizures, stroke, and psychosis.1,2 This clinical 
heterogeneity means accurate biomarkers are required to better define NPSLE. 
 
Human autoantibodies are one proposed biomarker. This field began with 
characterisation of a double-stranded DNA (dsDNA) reactive mouse 
monoclonal antibody (R4A). Upon transfer to mice, R4A led to glomerular 
deposition, a key feature of SLE pathology. Importantly, a peptide phage 
display library revealed R4A bound a consensus pentapeptide sequence (D/E-
W-D/E-Y-S/G, DWEYS for short) present within the extracellular domain of the 
NR2A and NR2B subunits of the N-methyl-D-aspartate receptor (NMDAR), and 
induced neuronal death in mice.3,4 Also, DWEYS-reactive B cell receptors 
isolated from SLE patients, including the G11 monoclonal antibody, were 
reported to bind NMDARs.5 These observations led to the proposal of NMDAR-
directed autoantibodies as pathogenic agents in NPSLE. 
 
Yet, human autoantibodies against NR2A/B subunit peptides have been 
disputed as a clinically useful test for NPSLE.6-8 A recent meta-analysis of 
~3000 subjects observed these serum autoantibodies in more patients with 
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SLE and Sjögren’s syndrome versus controls, but with only a modest increase 
in the neuropsychiatric subset.8 Very few studies presented parallel data from 
cerebrospinal fluid (CSF). 
 
An independent literature describes a clinically-distinctive form of encephalitis, 
with prominent neuropsychiatric features, which is consistently associated with 
serum and CSF autoantibodies against the native extracellular domain of the 
NMDAR NR1 subunit.9,10 These patients, with NMDAR-antibody encephalitis, 
very rarely have coexistent SLE, despite often being young females.9,10 Their 
NR1-reactive autoantibodies also bind the surface of live hippocampal neurons 
but not NR1-derived peptides, consistent with selectivity for native epitope 
confirmations.9-11 Similar exclusive binding to native, conformational surface 
proteins exists for other pathogenic neurological antibodies, directed against 
leucine-rich glioma inactivated 1 (LGI1), contactin-associated protein-like 2 
(CASPR2) and aquaporin-4 (AQP4).12,13 
 
Herein, we show that IgGs from sera and CSF of NPSLE patients neither react 
with surface-expressed native neuronal epitopes, nor show specificity towards 
peptides representing NMDARs. Our data support a fundamental need to 
redirect the search for biomarkers in human NPSLE, away from causative 
autoantibodies. 
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Patients and Methods 
Patient selection and involvement 
Paired plasma and CSF samples were frozen from 35 consecutive patients who 
met American College of Rheumatology (ACR) criteria for SLE, in a tertiary 
neuroinflammation clinic (Karolinska University Hospital, Sweden). Clinical and 
laboratory features were extracted retrospectively from case-notes. Control 
plasma and CSFs were from healthy controls (HC, n=36), with additional 
plasmas from CNS-autoimmunity disease controls (DC, n=68: multiple 
sclerosis (n=32) plus LGI1/CASPR2- (n=13), AQP4- (n=12) and NMDAR- 
(n=11) antibody mediated diseases). Study procedures and sample testing 
were ethically approved (Stockholm:2009/2107-31/2; 
Oxford:REC16/YH/0013). All assays were performed blinded to clinical details. 
 
Autoantibody determination and IFNα  measurements 
As previously described,10,14 plasma (1:20 dilution) and CSF (1:2 dilution) 
underwent live cell based assays (CBA) to detect autoantibodies against the 
extracellular domains of conformationally active NMDARs. Also, plasma 
(1:200) and CSF (1:2) were incubated with live cultured rodent hippocampal 
neurons after around day 18 in vitro. The DWEYS ELISA followed a published 
protocol,4 coating plates with either 20 µg/ml of DWEYSVWLSN (‘DWEYS'), a 
decapeptide with two substitutions (KWRYSVWLSN; with positively charged 
amino acids replacing negative ones), a randomly scrambled DWEYS 
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decapeptide (SDYVWLNESW) or no peptide. Plasma (1:500), CSF (1:1) and 
the humanised DWEYS monoclonal antibody (G11, kind gift from Prof 
Diamond, USA) were incubated for 1 hour prior to washing and incubation with 
anti-human/mouse HRP (1:2000 dilution, DAKO) followed by TMB (Bethyl) to 
develop the reaction. IFNα quantification utilised single molecule array 
(SIMOA) technology, as previously reported.15 
 
Results 
Patient and CSF characteristics 
At the time of assessment and sampling, median patient age was 47 years 
(range 18-77), 34/35 (97%) were female and 32/34 (94%) were receiving 
immunotherapies. 23/35 had active SLE and 15 active NPSLE, with multiple 
neurological features (Figure 1A).  
 
CSFs revealed raised CSF IgG in 11/35 (31%, normal range <45 mg/L), with 
accompanying raised IgG index in just one, and pleocytosis in 5/35 (14%, 
normal range <5 cells/µl). In addition, 12/35 (34%) showed a raised albumin 
quotient (normal range <7.1), consistent with blood-brain barrier dysfunction. 
No differences in these parameters were observed between subjects with and 
without NPSLE. 
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Absent binding of patient plasma/CSF IgGs to the extracellular domains 
of either expressed NMDARs or live neuronal cultures 
From live CBAs, surface expression of NR1/2 subunits was confirmed using 
commercial antibodies and the serum/CSF IgGs from NMDAR-antibody 
encephalitis patients (Figure 1B-C).9,10 However, the 35 SLE serum/CSF 
samples, HC sera and the G11 monoclonal antibody neither showed binding to 
the extracellular domains of mammalian cell expressed NR1/2A or NR1/2B 
heteromers nor to the array of native surface proteins expressed on live rodent 
primary hippocampal cultures (Figure 1B). This contrasted strikingly with the 
strong punctate somatic and dendritic binding observed with plasma/CSF IgGs 
from patients with encephalitis, including those with NMDAR- and CASPR2-
antibodies (Figure 1D).9,12 
 
Autoantibody binding to NMDAR-derived peptides is not peptide-specific 
Next, the original detection of DWEYS antibodies was revisited. On DWEYS-
coated ELISA plates, the anti-DWEYS G11 monoclonal bound clearly and an 
isotype control (B1) consistently showed ODs <0.3, both as predicted (Figure 
2A). Statistically significant differences were observed between SLE patients 
versus both HCs (p=0.03) and DCs (p=0.009). However, using a conservative 
cut-off, plasma IgG from 8/35 SLE patients, 2/36 HCs and 1/68 DC showed 
DWEYS reactivity (Figure 2A), and only 3/35 SLE samples, including one 
without active NPSLE, were clearly above all HC/DCs (Figure 2A). This 
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translated to ~23% sensitivity and ~97% specificity for detection of SLE, and 
did not distinguish the NPSLE cases. Similarly, CSF DWEYS reactivity did not 
discriminate between SLE and HCs, with a modest difference between active 
NPSLE and other SLE cases (p=0.021, Mann Whitney U; Figure 2B). Overall, 
the DWEYS IgG ELISA showed very limited specificity for NPSLE but cohort-
based differences revealed higher levels in SLE versus HC/DC plasmas. 
 
Next, this antigenic specificity was interrogated. Individual plasma samples 
showed very similar binding to the DWEYS peptide and to both the scrambled 
peptide ‘SDYVW’ (r=0.73, p<0.0001) and a substituted peptide ‘KWRYS’ 
(r=0.72, p<0.0001; Figure 2C-D). Furthermore, the DWEYS-reactivity from 
plasma and CSF correlated with binding to the uncoated ELISA plate (r=0.85, 
p<0.0001 and r=0.79, p<0.0001, respectively; Figure 2E). 
 
IFNα  levels better distinguish SLE from controls, but not from NPSLE 
Plasma IFNα levels were investigated as IFNα is associated with SLE, the 
development of neurological autoantibody-mediated complications in SLE, and 
is directly a neurotoxic cytokine.15-17 Plasma IFNα levels were ~100-fold higher 
in patients with SLE compared to HCs/DCs (both p<0.0001; Figure 3A), with 
less striking differences in CSF (Figure 3B). Consistent with their close 
correlations (Figure 3C), neither fluid distinguished active NPSLE from other 
SLE cases (Figure 3A-B). Using mean plus three standard deviations of HC 
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data as a cut-off for IFNα ‘positivity’, 22/35 (63%) SLE patients, 1/36 (3%) HC 
and 1/68 (1%) DC were positive in plasma, and 8/35 (23%) SLE patients and 
1/36 (1%) HC in CSF (sensitivities and specificities of ~63% and ~97% in 
plasma, and ~23% and ~99% in CSF). 
 
Discussion 
Our results show the absence of autoantibodies directed against 
conformationally-active neuronal surface targets, in both the plasma and CSF 
of patients with NPSLE. Furthermore, while SLE samples reacted more strongly 
with the DWEYS peptide, this binding appears to be accounted for by reactivity 
directly to the ELISA plate, suggesting a lack of antigenic specificity. The use 
of suitable antigen controls is therefore key in NPSLE studies, and may account 
for conflicting results in previous human reports. Taken together, our data 
suggest that autoantibodies have very limited clinical value in the definition or 
diagnosis of NPSLE and should prompt a search for novel biomarkers. IFNα is 
one such plausible candidate.15,16 However, while IFNα levels performed 
slightly better in distinguishing SLE from controls, they were also not enriched 
in the NPSLE subset. 
 
In routine neurology practice, autoantibodies which bind the surface of 
membrane proteins, such as the NMDAR, typically associate closely with a 
highly-distinctive clinical phenotype.9,10,12 These autoantibodies preferentially 
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react with conformationally-active, natively-expressed forms of the whole 
antigen: this confers pathogenic potential.9-13 However, we could not detect 
autoantibodies which react with the natural range of surface epitopes presented 
on cultured hippocampal neurons or, more specifically, the extracellular domain 
of native NMDARs in patients with SLE or NPSLE,18 despite proven adequate 
surface expression. 
 
Several observations question the clinical and pathogenic relevance of 
DWEYS-peptide reactive antibodies.7,8,19 Firstly, the DWEYS motif exists in 
multiple other human proteins, such as caeruloplasmin. Next, binding of a 
monoclonal antibody to a small peptide, without reacting with the full-length, 
conformational protein, is unlikely to mediate target-specific functional effects 
in vivo. Thirdly, DWEYS-reactive IgGs showed similar binding to scrambled and 
no peptide conditions. Hence, these antibodies do not specifically bind 
DWEYS. Rather, the physiochemical properties of naturally occurring self-
reactive antibodies, which are well described in SLE, are likely to account for 
their promiscuous binding characteristics.20 
 
Limitations of this study include a moderate cohort size and no examination of 
native glial or vascular reactivities, where the latter in particular may account 
for complement deposition observed in NPSLE brain tissue.21 In addition, we 
study only one cytokine and use rodent hippocampal neurons which in culture 
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may not to express key surface antigens for human NPSLE. Nevertheless, our 
use of parallel assays has been successful in the detection of >10 other likely 
pathogenic neurological autoantibodies previously,12,13 we test a sizeable set 
of CSFs and employ rigorous control peptides which accurately assess 
autoantibody specificity. 
 
Our observations suggest that the brain disease associated with SLE is likely 
to have pathological drivers other than neuronal surface autoantibodies. Future 
studies might take broader ‘omics’ approaches to assessing this clinically 
important manifestation of SLE, investigate innate immune components in 
greater detail and identify reliable biomarkers for diagnosis, monitoring and to 
better understand the primary pathology. 
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Figure legends 
Figure 1. Clinical features and immunoglobulin G (IgG) binding to 
conformational neuronal surface epitopes from plasma and cerebrospinal 
fluid (CSF) of patients with neuropsychiatric lupus (NPSLE). A. Clinical 
features of 35 patients with SLE, including 15 with active NPSLE at the time of 
sampling. 32/34 (94%) were on immunotherapies, including prednisolone 
(71%), hydroxychloroquine (41%), belimumab (6%) and rituximab (3%). ANA = 
anti-nuclear antibody. B. Live cell-based assays employing HEK293T cells with 
surface expressed N-methyl D-aspartate receptors (NMDARs) as NR1-NR2A 
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or NR1-NR2B heteromers (nuclei highlighted with DAPI, 4′,6-diamidino-2-
phenylindole). First panel shows that a commercial antibody directed against 
the extracellular domain of the NR2A-subunit (red) binds to HEK293T cells 
which express NR1-NR2A heteromers. NMDAR-antibody encephalitis 
(NMDAR-Ab-E) patient serum IgGs (n=11,) bind to the NR1-NR2A heteromers 
(second panel), and to NR1-NR2B heteromers / NR1 homomers (data not 
shown). NMDAR-antibody patient CSFs show similar binding (as Irani et al, 
2010).10 Serum from healthy controls (n=36), plasma and CSFs from SLE 
patients (n=35 of each) show no binding. No binding was observed with the 
G11 antibody (data not shown, lower panel representative). Throughout, IgG 
binding was visualized with an anti-human 568-Alexaflour antibody (1:750 
dilution, A-21090) C. Commercial antibodies against the extracellular domains 
of NR1 (Alomone, AGC-001), NR2A (Alomone, AGC-002) and NR2B (kind gift 
from Prof Stephenson, London) subunits bound to the surface of live HEK293T 
cells co-transfected with EGFP plus NR1 and NR2B subunits. D. Hippocampal 
neuron somae and dendrites are stained with a commercial antibody against 
microtubule associated protein 2 (MAP2, red). Live neurons in culture are 
robustly bound by IgGs from sera (top two panels) or CSF (data not shown) of 
patients with NMDAR-antibody encephalitis (n=11) and CASPR2-antibody 
encephalitis (n=5; CASPR2-Ab-E). However, no binding was detected using 
plasma / CSFs from 35 SLE patients and 36 sera from healthy controls. All 
scale bars =10 µm. 
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 Figure 2. Plasma and cerebrospinal fluid (CSF) reactivities against 
DWEYS and related peptides. A. Optical density (OD) results from the 
DWEYS ELISA, using G11 (humanized anti-DWEYS antibody), an isotype 
control (B1), and plasma from disease controls (n=68), healthy controls 
(n=36) and SLE patients (n=35), including those with active NPSLE. 
Significant differences (Kruskal Wallis test with post-hoc Dunn’s correction) 
were observed between SLE patients and healthy controls (p=0.03*) and 
disease controls (p=0.009**), but not between active NPSLE and other cases 
of SLE (ns). Cut-off for positivity (dotted line) represents the mean plus three 
standard deviations of healthy control values. B. From CSF, the DWEYS 
ELISA showed no difference between HCs and SLE, and modest difference 
within a comparison of SLE patients with active NPSLE versus others 
(p=0.021, Mann Whitney U test without correction for multiple comparisons). 
C and D. ELISA findings across all 35 SLE patients paralleled each other 
when using the DWEYS peptide, a scrambled peptide (SDYVWLNESW; 
Spearman’s r 0.72, p<0.0001) and a peptide with two positive amino acid 
substitutions (KWRYSVWLSN; Spearman’s r 0.73, p<0.0001). E. In both 
plasma (black) and CSF (grey, data multiplied ten fold), the ODs were highly 
correlated when performed in the presence versus absence of DWEYS 
peptide (Spearman’s rank r=0.85 and 0.79, respectively, both <0.0001). 
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Figure 3. Interferon alpha (IFNα ) levels in neuropsychiatric systemic 
lupus erythematosus (NPSLE). A. Plasma IFNα levels differentiate SLE 
from healthy controls (n=20) and from disease controls (n=32; both 
p<0.0001****, Kruskal Wallis with post hoc Dunn’s). There were no 
differences between SLE patients with active NPSLE versus those without 
(p=0.39). Comparisons of active NPSLE and other SLE versus both HC or DC 
all p<0.01 (data not charted). B. CSF IFNα does not differentiate between 
SLE and HC but does SLE and DC (p=0.02, Kruskal Wallis with post hoc 
Dunn’s). There was no difference between active NPSLE versus other SLE. 
IFNα levels in active NPSLE versus DC are significantly different (p=0.03) but 
not by comparison to HC. C. Overall, plasma and cerebrospinal fluid IFNα 
levels correlate closely (Spearman’s r=0.68, p< 0.0001) in both active NPSLE 
(r=0.75, p=0.002) and inactive NPSLE (r=0.59, p=0.007). 
 
 
 
 
 
This article is protected by copyright. All rights reserved.
For Peer Review
 
Figure 1. Clinical features and immunoglobulin G (IgG) binding to conformational neuronal 
surface epitopes from plasma and cerebrospinal fluid (CSF) of patients with neuropsychiatric 
lupus (NPSLE). A. Clinical features of 35 patients with SLE, including 15 with active NPSLE at the time of 
sampling. 32/34 (94%) were on immunotherapies, including prednisolone (71%), hydroxychloroquine 
(41%), belimumab (6%) and rituximab (3%). ANA = anti-nuclear antibody. B. Live cell-based assays 
employing HEK293T cells with surface expressed N-methyl D-aspartate receptors (NMDARs) as NR1-NR2A or 
NR1-NR2B heteromers (nuclei highlighted with DAPI, 4′,6-diamidino-2-phenylindole). First panel shows that 
a commercial antibody directed against the extracellular domain of the NR2A-subunit (red) binds to 
HEK293T cells which express NR1-NR2A heteromers. NMDAR-antibody encephalitis (NMDAR-Ab-E) patient 
serum IgGs (n=11) bind to the NR1-NR2A heteromers (second panel), and to NR1-NR2B heteromers / NR1 
homomers (data not shown). NMDAR-antibody patient CSFs show similar binding (as Irani et al, 2010).10 
Serum from healthy controls (n=36), plasma and CSFs from SLE patients (n=35 of each) show no binding. 
No binding was observed with the G11 antibody (data not shown, lower panel representative). Throughout, 
IgG binding was visualized with an anti-human 568-Alexaflour antibody (1:750 dilution, A-21090) C. 
Commercial antibodies against the extracellular domains of NR1 (Alomone, AGC-001), NR2A (Alomone, 
A
cc
ep
te
d 
A
rti
cl
e
This article is protected by copyright. All rights reserved.
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Figure 2. Plasma and cerebrospinal fluid (CSF) reactivities against DWEYS and related peptides. 
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(n=35), including those with active NPSLE. Significant differences (Kruskal Wallis test with post-hoc Dunn’s 
correction) were observed between SLE patients and healthy controls (p=0.03*) and disease controls 
(p=0.009**), but not between active NPSLE and other cases of SLE (ns). Cut-off for positivity (dotted line) 
represents the mean plus three standard deviations of healthy control values. B. From CSF, the DWEYS 
ELISA showed no difference between HCs and SLE, and modest difference within a comparison of SLE 
patients with active NPSLE versus others (p=0.021, Mann Whitney U test without correction for multiple 
comparisons). C and D. ELISA findings across all 35 SLE patients paralleled each other when using the 
DWEYS peptide, a scrambled peptide (SDYVWLNESW; Spearman’s r 0.72, p<0.0001) and a peptide with two 
positive amino acid substitutions (KWRYSVWLSN; Spearman’s r 0.73, p<0.0001). E. In both plasma (black) 
and CSF (grey, data multiplied ten fold), the ODs were highly correlated when performed in the presence 
versus absence of DWEYS peptide (Spearman’s rank r=0.85 and 0.79, respectively, both <0.0001). 
295x193mm (600 x 600 DPI) 
A
cc
ep
te
d 
A
rti
cl
e
This article is protected by copyright. All rights reserved.
 Figure 3. Interferon alpha (IFNα) levels in neuropsychiatric systemic lupus erythematosus 
(NPSLE). A. Plasma IFNα levels differentiate SLE from healthy controls (n=20) and from disease controls 
(n=32; both p<0.0001****, Kruskal Wallis with post hoc Dunn’s). There were no differences between SLE 
patients with active NPSLE versus those without (p=0.39). Comparisons of active NPSLE and other SLE 
versus both HC or DC all p<0.01 (data not charted). B. CSF IFNα does not differentiate between SLE and HC 
but does SLE and DC (p=0.02, Kruskal Wallis with post hoc Dunn’s). There was no difference between active 
NPSLE versus other SLE. IFNα levels in active NPSLE versus DC are significantly different (p=0.03) but not 
by comparison to HC. C. Overall, plasma and cerebrospinal fluid IFNα levels correlate closely (Spearman’s 
r=0.68, p< 0.0001) in both active NPSLE (r=0.75, p=0.002) and inactive NPSLE (r=0.59, p=0.007). 
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